Eighty female , chemotherapy-nave breast cancer patients ( median age @ , range @-@ years ) scheduled for four or five courses of adjuvant @ weekly doxorubicin plus cyclophosphamide ( AC ) chemotherapy , were randomly assigned to receive @mg PC-SOD ( human recombinant SOD bound to lecithin ) or placebo , administered intravenously ( i.v. ) immediately prior to each AC course .